Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients
Authors:
- Emin Tamer ElkiranEEEmin Tamer Elkiran
- Anatolian Society of Medical Oncology GroupAGAnatolian Society of Medical Oncology Group
- Mehmet Ali KaplanMKMehmet Ali Kaplan
- Alper SevincASAlper Sevinc
- Sercan AksoySASercan Aksoy
- Umut DemirciUDUmut Demirci
- Mesut SekerMSMesut Seker
- Hakan HarputluogluHHHakan Harputluoglu
- Nuriye Yildirim OzdemirNONuriye Yildirim Ozdemir
- Feridun IsikFIFeridun Isik
- Arife UlasAUArife Ulas
- Mevlude InancMIMevlude Inanc
- 22 June 2012
- journal article
- research article
- Published by Springer Nature in Medical Oncology
- Vol. 29 (5) , 3147-3154
Abstract
Malignant pleural mesothelioma (MPM) is a relatively rare, but aggressive tumor that causes high mortality. The major risk factor involved in the etiology is environmental and occupational exposure to asbestos. The optimal modality of therapy is controversial. The present study retrospectively evaluated the data pertinent to 282 patients who were examined and treated in 11 different medical oncology centers in Turkey. There were 161 males (57.1 %) and 121 females (42.9 %), with a mean age of 56.38 ± 12.07 years. Surgery was used in 74 patients, 21 patients (28.4 %) received only chemotherapy and 28 patients (37.8 %) received chemoradiotherapy after surgery. The median survival in patients who were administered adjuvant therapy after surgery was 24 months, while the median survival in patients who had only surgery was 6 months (p = 0.029). 106 patients were administered pemetrexed-platinum combination and 35 patients were administered gemcitabine-platinum combination as front-line chemotherapy. Median survival, 1- and 2-year survival rates in patients who received platinum analogues and pemetrexed or gemcitabine combinations were found statistically similar (p = 0.15). The median survival for all patients with MPM in our study was 18 months. The main factors influencing the overall survival were stage of the disease (p = 0.020), performance status (p < 0.001), asbestos exposure (p = 0.030) and mesothelioma histological subtypes (p < 0.001). Results of our study suggest that multi-modality treatment regimens consisting of surgery, radiotherapy and chemotherapy prolong overall survival. Survival rates in patients who received combining platinum analogues with pemetrexed or gemcitabine as front-line chemotherapy were found similar.Keywords
This publication has 66 references indexed in Scilit:
- Time trend of mesothelioma incidence in the United States and projection of future cases: An update based on SEER data for 1973 through 2005Critical Reviews in Toxicology, 2009
- Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trialThe Lancet, 2008
- Malignant pleural mesothelioma: current concepts in treatmentNature Clinical Practice Oncology, 2007
- Incidence of Malignant Pleural Mesothelioma due to Environmental Asbestos Fiber Exposure in the Southeast of TurkeyRespiration, 2000
- Malignant pleural mesotheliomaEuropean Respiratory Journal, 1998
- 779 Malignant pleural mesothelioma in childhood: A case reportLung Cancer, 1997
- Malignant mesothelioma in south east England: clinicopathological experience of 272 cases [published erratum appears in Thorax 1997 Nov;52(11):1018]Thorax, 1997
- Epidemiological and environmental evidence of the health effects of exposure to erionite fibres: A four‐year study in the cappadocian region of turkeyInternational Journal of Cancer, 1987
- Malignant mesothelioma 1982: Review of 4710 published casesRespiratory Medicine, 1983
- Pleural biopsy in the diagnosis of malignant mesothelioma.Thorax, 1982